Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Voluntis

DB:9VO
Snowflake Description

Imperfect balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
9VO
DB
€9M
Market Cap
  1. Home
  2. DE
  3. Healthcare
Company description

Voluntis S.A. develops digital therapeutic solutions for diabetes, oncology, and other therapeutic areas in France and the United States. The last earnings update was 12 days ago. More info.


Add to Portfolio Compare Print
  • Voluntis has significant price volatility in the past 3 months.
9VO Share Price and Events
7 Day Returns
-23.9%
DB:9VO
10.8%
DE Healthcare Services
4.3%
DE Market
1 Year Returns
-79.3%
DB:9VO
14.2%
DE Healthcare Services
-14.2%
DE Market
9VO Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Voluntis (9VO) -23.9% -27% -55.7% -79.3% - -
DE Healthcare Services 10.8% 3% -3.8% 14.2% 47.1% 117.7%
DE Market 4.3% -9% -21.6% -14.2% -19.6% -25.6%
1 Year Return vs Industry and Market
  • 9VO underperformed the Healthcare Services industry which returned 14.2% over the past year.
  • 9VO underperformed the Market in Germany which returned -14.2% over the past year.
Price Volatility
Industry
5yr Volatility vs Market

Value

 Is Voluntis undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Voluntis. This is due to cash flow or dividend data being unavailable. The share price is €0.975.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Voluntis's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Voluntis's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:9VO PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in EUR €-2.15
ENXTPA:VTX Share Price ** ENXTPA (2020-04-07) in EUR €1.13
Germany Healthcare Services Industry PE Ratio Median Figure of 6 Publicly-Listed Healthcare Services Companies 11.55x
Germany Market PE Ratio Median Figure of 402 Publicly-Listed Companies 17.07x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Voluntis.

DB:9VO PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ENXTPA:VTX Share Price ÷ EPS (both in EUR)

= 1.13 ÷ -2.15

-0.53x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Voluntis is loss making, we can't compare its value to the DE Healthcare Services industry average.
  • Voluntis is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Voluntis's expected growth come at a high price?
Raw Data
DB:9VO PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.53x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
55.1%per year
Europe Healthcare Services Industry PEG Ratio Median Figure of 14 Publicly-Listed Healthcare Services Companies 2.67x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.24x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Voluntis, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Voluntis's assets?
Raw Data
DB:9VO PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in EUR €1.20
ENXTPA:VTX Share Price * ENXTPA (2020-04-07) in EUR €1.13
Germany Healthcare Services Industry PB Ratio Median Figure of 7 Publicly-Listed Healthcare Services Companies 2.86x
Germany Market PB Ratio Median Figure of 573 Publicly-Listed Companies 1.47x
DB:9VO PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ENXTPA:VTX Share Price ÷ Book Value per Share (both in EUR)

= 1.13 ÷ 1.20

0.94x

* Primary Listing of Voluntis.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Voluntis is good value based on assets compared to the DE Healthcare Services industry average.
X
Value checks
We assess Voluntis's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Healthcare Services industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Healthcare Services industry average (and greater than 0)? (1 check)
  5. Voluntis has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Voluntis expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
55.1%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Voluntis expected to grow at an attractive rate?
  • Unable to compare Voluntis's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Voluntis's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Voluntis's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:9VO Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:9VO Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts 55.1%
DB:9VO Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 2 Analysts 75.1%
Europe Healthcare Services Industry Earnings Growth Rate Market Cap Weighted Average 26.9%
Europe Healthcare Services Industry Revenue Growth Rate Market Cap Weighted Average 8%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:9VO Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:9VO Future Estimates Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-12-31 40 -4 -5 1
2020-12-31 29 -10 -8 1
2020-04-08
DB:9VO Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2019-12-31 4 -12 -16
2019-09-30 4 -14 -16
2019-06-30 4 -15 -16
2019-03-31 4 -15 -16
2018-12-31 5 -15 -16
2018-09-30 4 -12 -15
2018-06-30 4 -9 -15
2018-03-31 6 -7 -13
2017-12-31 7 -5 -10

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Voluntis is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Voluntis's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:9VO Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from Voluntis Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:9VO Future Estimates Data
Date (Data in EUR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-12-31 -0.68 -0.68 -0.68 1.00
2020-12-31 -1.08 -1.08 -1.08 1.00
2020-04-08
DB:9VO Past Financials Data
Date (Data in EUR Millions) EPS *
2019-12-31
2019-09-30
2019-06-30 -2.15
2019-03-31 -2.30
2018-12-31 -2.48
2018-09-30 -2.70
2018-06-30 -2.99
2018-03-31 -2.59
2017-12-31 -2.15

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Voluntis will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Voluntis's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Europe market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Europe market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Voluntis has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Voluntis performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Voluntis's growth in the last year to its industry (Healthcare Services).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Voluntis does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Voluntis's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Voluntis's 1-year growth to the DE Healthcare Services industry average as it is not currently profitable.
Earnings and Revenue History
Voluntis's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Voluntis Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:9VO Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 3.70 -15.80
2019-09-30 4.02 -16.05 0.00
2019-06-30 4.33 -16.29 -0.01
2019-03-31 4.43 -16.11 0.14
2018-12-31 4.53 -15.94 0.28
2018-09-30 4.19 -15.50 0.31
2018-06-30 3.84 -15.06 0.34
2018-03-31 5.57 -12.54 0.24
2017-12-31 7.30 -10.03 0.13
2016-12-31 10.27 -4.86

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Voluntis has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Voluntis has efficiently used its assets last year compared to the DE Healthcare Services industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Voluntis improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Voluntis's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Healthcare Services industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Voluntis has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Voluntis's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Voluntis's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Voluntis is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Voluntis's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Voluntis's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 2.4x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Voluntis Company Filings, last reported 3 months ago.

DB:9VO Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 1.70 7.70 5.10
2019-09-30 1.70 7.70 5.10
2019-06-30 9.07 5.69 14.21
2019-03-31 9.07 5.69 14.21
2018-12-31 17.30 3.64 19.87
2018-09-30 17.30 3.64 19.87
2018-06-30 24.95 3.88 28.82
2018-03-31 24.95 3.88 28.82
2017-12-31 -1.13 4.26 1.85
2016-12-31 2.10 7.01 5.83
  • Voluntis's level of debt (258.8%) compared to net worth is high (greater than 40%).
  • Unable to establish if Voluntis's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Voluntis has less than a year of cash runway based on current free cash flow.
  • Voluntis has less than a year of cash runway if free cash flow continues to grow at historical rates of 27.7% each year.
X
Financial health checks
We assess Voluntis's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Voluntis has a total score of 2/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Voluntis's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Voluntis dividends.
If you bought €2,000 of Voluntis shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Voluntis's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Voluntis's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:9VO Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
Europe Healthcare Services Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 1.4%
Germany Market Average Dividend Yield Market Cap Weighted Average of 314 Stocks 3.6%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.6%
Germany Top 25% Dividend Yield 75th Percentile 4.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:9VO Future Dividends Estimate Data
Date (Data in €) Dividend per Share (annual) Avg. No. Analysts
2021-12-31
2020-12-31
2020-04-08

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Voluntis has not reported any payouts.
  • Unable to verify if Voluntis's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Voluntis's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Voluntis has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Voluntis's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Voluntis afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Voluntis has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Voluntis's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Pierre Leurent
COMPENSATION €457,773
AGE 40
CEO Bio

Mr. Pierre Leurent founded Voluntis SA in 2001 and serves as its Chief Executive Officer. Mr. Leurent served as President of The Executive Board at Voluntis SA until April 11, 2018. Mr. Leurent served as Chairman of the Board of Voluntis SA. Mr. Leurent has been Director of Voluntis S.A. since April 11, 2018. He has more than 15 years of international experience in software medical devices, disease management and telemedicine solutions in Europe and the United States. Before founding Voluntis in 2001, he worked with General Electric Medical Systems and with HealthCenter Internet Services, an online cardiology EMR solution vendor in San Francisco. In addition, he is the Director of Syntec Numérique, where he leads the telemedicine workgroup, co-leader of CSIS-CSF’s e-health workgroup and e-health advisor within Nouvelle France Industrielle’s health steering committee. Mr. Leurent is a graduate of the Ecole Centrale Paris engineering school.

CEO Compensation
  • Pierre's compensation has increased whilst company is loss making.
  • Pierre's remuneration is about average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Voluntis management team in years:

10.3
Average Tenure
40
Average Age
  • The average tenure for the Voluntis management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Pierre Leurent

TITLE
Founder
COMPENSATION
€458K
AGE
40

Romain Marmot

TITLE
Co-Founder
COMPENSATION
€274K
AGE
39
TENURE
19.3 yrs

Alexandre Capet

TITLE
Deputy CEO
COMPENSATION
€318K
AGE
45

Etienne Vial

TITLE
Senior VP of Research & Development and Co-Founder
TENURE
19.3 yrs

Matthieu Plessis

TITLE
Director of Administration & Finance

Patrick Alff

TITLE
Chief Technology Officer

Damien McKeon

TITLE
Senior Vice President of Real-World Evidence
TENURE
1.3 yrs

Geneviève D'Orsay

TITLE
Chief Medical Officer

Raffi Krikorian

TITLE
Senior Vice President of Global Quality & Regulatory Affairs
TENURE
1.3 yrs

Aurore Beaume

TITLE
Head of Business Development - Europe
Board of Directors Tenure

Average tenure and age of the Voluntis board of directors in years:

2
Average Tenure
52
Average Age
  • The average tenure for the Voluntis board of directors is less than 3 years, this suggests a new board.
Board of Directors

Eric Elliott

TITLE
Chairman of the Board of Directors
COMPENSATION
€53K
AGE
55
TENURE
2 yrs

Pierre Leurent

TITLE
Founder
COMPENSATION
€458K
AGE
40
TENURE
2 yrs

Nicolas Cartier

TITLE
Independent Director
AGE
51

Viviane Monges

TITLE
Independent Director
AGE
56
TENURE
2 yrs

Alain Parthoens

TITLE
Observer
AGE
59
TENURE
2 yrs

Franck Noiret

TITLE
Director
AGE
52
TENURE
2 yrs

Jan Berger

TITLE
Independent Director
AGE
60
TENURE
1.5 yrs

Roberta Herman

TITLE
Independent Director
TENURE
1.5 yrs

Tim Jackson

TITLE
Observer
AGE
36
TENURE
2 yrs

Laurent Higueret

TITLE
Director
AGE
39
TENURE
2 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Voluntis's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Voluntis has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Voluntis S.A. develops digital therapeutic solutions for diabetes, oncology, and other therapeutic areas in France and the United States. It offers Insulia, a prescription medical device that provides automated basal insulin dose recommendations and coaching messages for people with type 2 diabetes; and Diabeo, a digital solution for type 1 and type 2 patients treated on a basal-bolus insulin regimen, which suggests insulin dosage, through algorithmic calculations that are specific to the patient and based on their particular doses. The company provides Oleena, a first FDA class II software-as-a-medical device for cancer indications; AstraZeneca, an e-Cediranib Olaparib application designed for patient self-reporting and management of hypertension and diarrhea; Theraxium Oncology, a cornerstone software platform for all digital therapeutics of cancer treatment, as well as coagulation and hemophilia solutions. Voluntis S.A. has a collaboration agreement with Bristol-Myers Squibb Company to co-develop digital Therapeutics for Oncology. Voluntis S.A. was founded in 2001 and is based in Suresnes, France.

Details
Name: Voluntis S.A.
9VO
Exchange: DB
Founded: 2001
€8,534,340
7,552,514
Website: http://www.voluntis.com
Address: Voluntis S.A.
22 Quai Gallieni,
Suresnes,
Ile-de-France, 92150,
France
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ENXTPA VTX Common Shares Euronext Paris FR EUR 30. May 2018
DB 9VO Common Shares Deutsche Boerse AG DE EUR 30. May 2018
Number of employees
Current staff
Staff numbers
111
Voluntis employees.
Industry
Health Care Technology
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/08 04:51
End of day share price update: 2020/04/07 00:00
Last estimates confirmation: 2020/03/27
Last earnings filing: 2020/03/27
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.